GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Amylyx Pharmaceuticals Inc (NAS:AMLX) » Definitions » Days Payable

Amylyx Pharmaceuticals (Amylyx Pharmaceuticals) Days Payable : 138.59 (As of Dec. 2023)


View and export this data going back to 2022. Start your Free Trial

What is Amylyx Pharmaceuticals Days Payable?

Amylyx Pharmaceuticals's average Accounts Payable for the three months ended in Dec. 2023 was $14.2 Mil. Amylyx Pharmaceuticals's Cost of Goods Sold for the three months ended in Dec. 2023 was $9.4 Mil. Hence, Amylyx Pharmaceuticals's Days Payable for the three months ended in Dec. 2023 was 138.59.

The historical rank and industry rank for Amylyx Pharmaceuticals's Days Payable or its related term are showing as below:

AMLX' s Days Payable Range Over the Past 10 Years
Min: 201.3   Med: 425.63   Max: 648.11
Current: 201.3

During the past 5 years, Amylyx Pharmaceuticals's highest Days Payable was 648.11. The lowest was 201.30. And the median was 425.63.

AMLX's Days Payable is ranked better than
57.88% of 717 companies
in the Biotechnology industry
Industry Median: 151.69 vs AMLX: 201.30

Amylyx Pharmaceuticals's Days Payable declined from Dec. 2022 (215.25) to Dec. 2023 (138.59). It may suggest that Amylyx Pharmaceuticals accelerated paying its suppliers.


Amylyx Pharmaceuticals Days Payable Historical Data

The historical data trend for Amylyx Pharmaceuticals's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amylyx Pharmaceuticals Days Payable Chart

Amylyx Pharmaceuticals Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Days Payable
- - - 648.11 203.14

Amylyx Pharmaceuticals Quarterly Data
Dec19 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Days Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 215.25 147.05 289.98 271.63 138.59

Competitive Comparison of Amylyx Pharmaceuticals's Days Payable

For the Biotechnology subindustry, Amylyx Pharmaceuticals's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Amylyx Pharmaceuticals's Days Payable Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Amylyx Pharmaceuticals's Days Payable distribution charts can be found below:

* The bar in red indicates where Amylyx Pharmaceuticals's Days Payable falls into.



Amylyx Pharmaceuticals Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Amylyx Pharmaceuticals's Days Payable for the fiscal year that ended in Dec. 2023 is calculated as

Days Payable (A: Dec. 2023 )
=Average Accounts Payable /Cost of Goods Sold*Days in Period
=( (Accounts Payable (A: Dec. 2022 ) + Accounts Payable (A: Dec. 2023 )) / count ) / Cost of Goods Sold (A: Dec. 2023 )*Days in Period
=( (6.257 + 22.061) / 2 ) / 25.441*365
=14.159 / 25.441*365
=203.14

Amylyx Pharmaceuticals's Days Payable for the quarter that ended in Dec. 2023 is calculated as:

Days Payable (Q: Dec. 2023 )
=Average Accounts Payable / Cost of Goods Sold*Days in Period
=( (Accounts Payable (Q: Sep. 2023 ) + Accounts Payable (Q: Dec. 2023 )) / count ) / Cost of Goods Sold (Q: Dec. 2023 )*Days in Period
=( (6.371 + 22.061) / 2 ) / 9.36*365 / 4
=14.216 / 9.36*365 / 4
=138.59

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Amylyx Pharmaceuticals Days Payable Related Terms

Thank you for viewing the detailed overview of Amylyx Pharmaceuticals's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.


Amylyx Pharmaceuticals (Amylyx Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
43 Thorndike Street, Cambridge, MA, USA, 02141
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases.
Executives
Joshua B Cohen director, officer: Co-Chief Executive Officer C/O AMYLYX PHARMACEUTICALS, INC., 43 THORNDIKE STREET, CAMBRIDGE MA 02141
Justin B. Klee director, officer: Co-Chief Executive Officer C/O AMYLYX PHARMACEUTICALS, INC., 43 THORNDIKE STREET, CAMBRIDGE MA 02141
Patrick D Yeramian officer: Chief Medical Officer 1815 PARKSIDE CIRCLE SOUTH, BOCA RATON FL 33486
James M Frates officer: Chief Financial Officer 88 SIDNEY ST, CAMBRIDGE MA 021394136
Karen Firestone director C/O AMYLYX PHARMACEUTICALS, INC., 43 THORNDIKE ST., CAMBRIDGE MA 02141
Gina Mazzariello officer: Chief Legal Officer C/O AMYLYX PHARMACEUTICALS, INC., 43 THORNDIKE STREET, CAMBRIDGE MA 02141
Morningside Venture Investments Ltd 10 percent owner MCCARTHY LEGAL SERVICES, 1188 CENTRE STREET, NEWTON CENTRE MA 02459
Milne George M Jr director
Margaret Olinger officer: Chief Commercial Officer C/O AMYLYX PHARMACEUTICALS, INC., 43 THORNDIKE STREET, CAMBRIDGE MA 02141
Viking Global Investors Lp 10 percent owner 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Dragsa 96 Llc 10 percent owner 55 RAILROAD AVE., GREENWICH CT 06830
Als Invest 1 B.v. 10 percent owner EERSTE WELERINGDWARSSTRAAL 54E, 1017 TP, AMSTERDAM P7 1017
Isaac Cheng director C/O ATEA PHARMACEUTICALS, INC., 125 SUMMER STREET, BOSTON MA 02110
Mvil, Llc 10 percent owner 22ND FLOOR HANG LUNG CENTRE, 2-20 PATERSON STREET, CAUSEWAY BAY K3 00000
Ole Andreas Halvorsen 10 percent owner 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901